CRVS
Corvus Pharmaceuticals Inc
11.80$
-5.9%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 100.0% | 97.2% | 96.3% | 95.0% | 96.9% | 94.9% | 53.0% | 65.2% | 64.0% | 61.4% | 79.0% | 81.9% | |
| 99.9% | 4.2% | 96.3% | 95.0% | 96.9% | 6.2% | 19.2% | 58.0% | 19.3% | 27.7% | 12.7% | 6.4% | |
| 99.9% | 95.9% | 96.3% | 95.0% | 96.9% | 93.2% | 51.7% | 63.5% | 62.0% | 59.6% | 75.4% | 79.8% | |
| – | 0.4% | 0.3% | 0.1% | 0.3% | 0.4% | 0.1% | 0.5% | 0.9% | 0.1% | 0.3% | 0.5% | |
| – | 0.7% | -0.8% | -0.9% | -0.5% | -1.0% | -0.6% | -0.6% | -1.1% | – | – | – | |
| 14.7% | 1.9% | 2.3% | 2.8% | 1.8% | 4.5% | 3.0% | 3.3% | – | – | – | – | |
| – | – | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| – | – | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 101.3% | 131.6% | 5.2% | 10.5% | 6.7% | 15.0% | 15.6% | 11.2% | 17.8% | 15.1% | 52.7% | 13.9% | |
| 21.3% | 3.1% | 5.2% | 10.5% | 6.7% | 12.2% | 14.2% | 8.9% | 15.8% | 15.1% | 51.4% | 13.2% | |
| 20.8% | -0.2% | – | – | – | 1.0% | 1.3% | 1.0% | 1.8% | 3.0% | 0.3% | 0.6% | |
| 0.5% | 1.6% | 1.4% | 3.6% | 1.7% | 2.9% | 4.1% | 1.4% | 2.9% | 3.3% | 3.7% | 3.5% | |
| – | – | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| -1.3% | -31.6% | 94.8% | 89.5% | 93.3% | 85.0% | 84.4% | 88.8% | 82.2% | 84.9% | 47.3% | 86.1% | |
| -1.3% | -32.0% | -48.4% | -130.3% | -144.2% | -259.6% | -260.9% | -243.4% | -450.9% | -734.8% | -576.2% | -579.7% | |
| 1.4% | 20.7% | 11.0% | 21.6% | 23.3% | 35.1% | 34.5% | 38.2% | 68.2% | 105.4% | 88.5% | 112.1% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.